Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program

Authors

Stefanie Geisler, Washington University School of Medicine in St. Louis
Ryan A Doan, Washington University School of Medicine in St. Louis
Galen C Cheng, Washington University School of Medicine in St. Louis
Aysel Cetinkaya-Fisgin, Johns Hopkins University
Shay X Huang, Washington University School of Medicine in St. Louis
Ahmet Höke, Johns Hopkins University
Jeffrey Milbrandt, Washington University School of Medicine in St. Louis
Aaron DiAntonio, Washington University School of Medicine in St. Louis

Journal

JCI Insight

Publication Date

9-5-2019

Volume

4

Issue

17

First Page

e129920

Document Type

Open Access Publication

DOI

10.1172/jci.insight.129920

Rights and Permissions

Geisler S, Doan RA, Cheng GC, Cetinkaya-Fisgin A, Huang SX, Höke A, Milbrandt J, DiAntonio A. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight. 2019 Sep 5;4(17):e129920. doi: 10.1172/jci.insight.129920. PMID: 31484833; PMCID: PMC6777905.

Recommended Citation

Geisler, Stefanie; Doan, Ryan A; Cheng, Galen C; Cetinkaya-Fisgin, Aysel; Huang, Shay X; Höke, Ahmet; Milbrandt, Jeffrey; and DiAntonio, Aaron, "Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program." JCI Insight. 4, 17. e129920 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9709